Consumers in the US saw branded drug prices rise by 14.8% last year, according to Truveris, a leading platform for prescription drug pricing and benefits analysis. In turn, speciality drugs rose 9.7%, while generics rose by 4.9%.
All therapeutic classes rose in price, but notable rises (across brand, generic and speciality) included muscle pain and stiffness (29.8%), inflammation (26.6%), chronic obstructive pulmonary disease (23.0%) and heart disease (19.4%).
"Drug costs across all categories are becoming an escalating concern for patients, employers, insurers and lawmakers," said Bryan Birch, Chairman, President and CEO of Truveris.
"Looking at macro industry trends, including consolidation, regulation and formulary pressures, we expect this price inflation to continue to put pressure on American households and employers in 2015."
